Category: blood cancer

Dr. Amit Agarwal Interview

best oncologist, blood cancer, breast cancer, Cancer Treatment, Dr. Interview, News / July 3, 2021 July 3, 2021

Sonam: Hello everyone, today we have on our panel discussion round doctor Amit Agarwal with us who is Director Medical Oncology from Fortis Hospital Shalimar Bagh. We welcome your doctor on board. Dr. Amit: Thank you Sonam: So to let you know about Doctor Amit. Doctor Amit brings with him an experience of more than …

Dr. Amit Agarwal Interview Read More »

TG Therapeutics completes FDA filing for Roche challenger in CLL

blood cancer, chronic lymphocytic leukaemia, News, Oncology, Roche, TG Therapeutics / March 30, 2021 March 30, 2021

TG Therapeutics has completed its rolling FDA filing for its U2 combination therapy consisting of the antibody ublituximab with the oral drug Ukoniq (umbralisib) as a treatment for chronic lymphocytic leukaemia (CLL). The US pharma is mounting a challenge to Roche, which markets an antibody therapy, Gazyvaro (obinutuzumab) in advanced CLL. Like Gazyvaro, ublituximab targets …

TG Therapeutics completes FDA filing for Roche challenger in CLL Read More »

TG Therapeutics challenges Roche with FDA filing for CLL drug

blood cancer, chronic lymphocytic leukaemia, CLL, FDA, News, Oncology, Roche, TG Therapeutics / December 2, 2020 December 2, 2020

US biotech TG Therapeutics has begun a rolling filing with the FDA for its combination therapy for chronic lymphocytic leukaemia, in a challenge to Roche. The New York-based firm has requested approval for the combination of its anti-CD20 antibody ublituximab and umralisib, an oral drug that inhibits PI3K-delta and CK-1 epsilon. The FDA had already …

TG Therapeutics challenges Roche with FDA filing for CLL drug Read More »

Imago raises $80M to further studies of its treatment for blood and bone-marrow disorders

Amgen Ventures, BioPharma, biopharma nl, Blackstone, blood cancer, bone marrow cancer drugs, Clarus Ventures, Daily, Farallon Capital Management, FDA, FerroKin BioSciences, frazier healthcare partners, Greenspring Associates, Highlight Capital, Imago BioSciences, Irving Investors, Kindgon Capital Management, MRL Ventures Fund, News, Omega Funds, Pharmaron Investments, Shire, Startups, Surveyor Capital, SYN, Top Story, Xeraya Capital / November 19, 2020 November 19, 2020

The San Francisco-based company aims to complete at least one Phase III study by 2025, and it is weighing an IPO next year to fund more.